China Shineway Pharmaceutical
China Shineway Pharmaceutical Group Limited, commonly referred to as Shineway Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1997, the company has made significant strides in the development and manufacturing of traditional Chinese medicine and modern pharmaceuticals, with a strong operational presence across Asia and beyond. Shineway Pharmaceutical is renowned for its core products, including herbal medicines and innovative therapeutic solutions, which are distinguished by their quality and efficacy. The company has achieved notable milestones, such as receiving various certifications for its manufacturing processes, solidifying its reputation in the market. With a commitment to research and development, Shineway continues to enhance its product offerings, positioning itself as a leader in the pharmaceutical sector and contributing to the global healthcare landscape.
DitchCarbon Score
How does China Shineway Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Shineway Pharmaceutical's score of 37 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Shineway Pharmaceutical's reported carbon emissions
In 2023, China Shineway Pharmaceutical reported total carbon emissions of approximately 140,340,570 kg CO2e. This figure includes 80,760,440 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 38,727,160 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company recorded Scope 3 emissions of about 20,852,970 kg CO2e, which encompass all other indirect emissions that occur in the value chain. Comparatively, in 2022, the total emissions were about 141,380,020 kg CO2e, with Scope 1 emissions at 87,499,150 kg CO2e and Scope 2 emissions at 30,190,360 kg CO2e, while Scope 3 emissions were approximately 23,690,510 kg CO2e. This indicates a slight reduction in total emissions from 2022 to 2023. Despite these figures, China Shineway Pharmaceutical has not publicly committed to specific reduction targets or initiatives, as there are no documented reduction targets or climate pledges available. The company continues to disclose its emissions across all three scopes, demonstrating transparency in its reporting practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 117,620,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 8,186,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 27,604,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Shineway Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
